Aeovian Pharmaceuticals aims to discover, develop, and commercialize therapeutics for the treatment of rare and age-related diseases.
Aeovian Pharmaceuticals has raised $55.0M in total funding. The most recent round was Series B. The last funding was announced in December 2025.
Aeovian Pharmaceuticals's investors include Foresite Capital, Sofinnova Investments, Evotec, b2venture, Apollo Health Ventures.
Aeovian Pharmaceuticals is headquartered in San Francisco, United States.
Aeovian Pharmaceuticals aims to discover, develop, and commercialize therapeutics for the treatment of rare and age-related diseases.
Aeovian Pharmaceuticals is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aeovian Pharmaceuticals — Funding & Investors." VCBacked, December 16, 2025, https://www.vcbacked.co/company/aeovian-pharmaceuticals. Accessed July 20, 2026.
VCBacked. (2025). Aeovian Pharmaceuticals — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/aeovian-pharmaceuticals
{{cite web |title=Aeovian Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/aeovian-pharmaceuticals |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated